The global Crohn鈥檚 Disease Therapeutics market size was valued at USD 3416.4 million in 2023 and is forecast to a readjusted size of USD 3750 million by 2030 with a CAGR of 1.3% during review period.
Prevalence of Crohn鈥檚 disease has increased in developing countries owing to industrialization, environmental factors such as differences in exposure to sunlight, changes in diet, smoking, and genetic characteristics. According to the Centers for Disease Control and Prevention (CDC), over 1 million Americans suffer from inflammatory bowel disease every year.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report includes an overview of the development of the Crohn鈥檚 Disease Therapeutics industry chain, the market status of Hospitals (Non-Surgical, Surgical), Ambulatory Surgical Centers (Non-Surgical, Surgical), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Crohn鈥檚 Disease Therapeutics.
Regionally, the report analyzes the Crohn鈥檚 Disease Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Crohn鈥檚 Disease Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Crohn鈥檚 Disease Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Crohn鈥檚 Disease Therapeutics industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Non-Surgical, Surgical).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Crohn鈥檚 Disease Therapeutics market.
Regional Analysis: The report involves examining the Crohn鈥檚 Disease Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Crohn鈥檚 Disease Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Crohn鈥檚 Disease Therapeutics:
Company Analysis: Report covers individual Crohn鈥檚 Disease Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Crohn鈥檚 Disease Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospitals, Ambulatory Surgical Centers).
Technology Analysis: Report covers specific technologies relevant to Crohn鈥檚 Disease Therapeutics. It assesses the current state, advancements, and potential future developments in Crohn鈥檚 Disease Therapeutics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Crohn鈥檚 Disease Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Crohn鈥檚 Disease Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Non-Surgical
Surgical
麻豆原创 segment by Application
Hospitals
Ambulatory Surgical Centers
麻豆原创 segment by players, this report covers
Johnson and Johnson Services Inc.
Pfizer Inc.
Allergan
AbbVie Inc.
Takeda Pharmaceutical Company Limited
Celgene Corporation
Perrigo Company PLC
Ferring B.V.
Salix Pharmaceuticals
Gilead Sciences Inc.
Genentech Inc.
UCB India Private Limited.
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Crohn鈥檚 Disease Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Crohn鈥檚 Disease Therapeutics, with revenue, gross margin and global market share of Crohn鈥檚 Disease Therapeutics from 2019 to 2024.
Chapter 3, the Crohn鈥檚 Disease Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Crohn鈥檚 Disease Therapeutics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Crohn鈥檚 Disease Therapeutics.
Chapter 13, to describe Crohn鈥檚 Disease Therapeutics research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of Crohn鈥檚 Disease Therapeutics
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Crohn鈥檚 Disease Therapeutics by Type
1.3.1 Overview: Global Crohn鈥檚 Disease Therapeutics 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Crohn鈥檚 Disease Therapeutics Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Non-Surgical
1.3.4 Surgical
1.4 Global Crohn鈥檚 Disease Therapeutics 麻豆原创 by Application
1.4.1 Overview: Global Crohn鈥檚 Disease Therapeutics 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospitals
1.4.3 Ambulatory Surgical Centers
1.5 Global Crohn鈥檚 Disease Therapeutics 麻豆原创 Size & Forecast
1.6 Global Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast by Region
1.6.1 Global Crohn鈥檚 Disease Therapeutics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Crohn鈥檚 Disease Therapeutics 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Johnson and Johnson Services Inc.
2.1.1 Johnson and Johnson Services Inc. Details
2.1.2 Johnson and Johnson Services Inc. Major Business
2.1.3 Johnson and Johnson Services Inc. Crohn鈥檚 Disease Therapeutics Product and Solutions
2.1.4 Johnson and Johnson Services Inc. Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Johnson and Johnson Services Inc. Recent Developments and Future Plans
2.2 Pfizer Inc.
2.2.1 Pfizer Inc. Details
2.2.2 Pfizer Inc. Major Business
2.2.3 Pfizer Inc. Crohn鈥檚 Disease Therapeutics Product and Solutions
2.2.4 Pfizer Inc. Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Pfizer Inc. Recent Developments and Future Plans
2.3 Allergan
2.3.1 Allergan Details
2.3.2 Allergan Major Business
2.3.3 Allergan Crohn鈥檚 Disease Therapeutics Product and Solutions
2.3.4 Allergan Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Allergan Recent Developments and Future Plans
2.4 AbbVie Inc.
2.4.1 AbbVie Inc. Details
2.4.2 AbbVie Inc. Major Business
2.4.3 AbbVie Inc. Crohn鈥檚 Disease Therapeutics Product and Solutions
2.4.4 AbbVie Inc. Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 AbbVie Inc. Recent Developments and Future Plans
2.5 Takeda Pharmaceutical Company Limited
2.5.1 Takeda Pharmaceutical Company Limited Details
2.5.2 Takeda Pharmaceutical Company Limited Major Business
2.5.3 Takeda Pharmaceutical Company Limited Crohn鈥檚 Disease Therapeutics Product and Solutions
2.5.4 Takeda Pharmaceutical Company Limited Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
2.6 Celgene Corporation
2.6.1 Celgene Corporation Details
2.6.2 Celgene Corporation Major Business
2.6.3 Celgene Corporation Crohn鈥檚 Disease Therapeutics Product and Solutions
2.6.4 Celgene Corporation Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Celgene Corporation Recent Developments and Future Plans
2.7 Perrigo Company PLC
2.7.1 Perrigo Company PLC Details
2.7.2 Perrigo Company PLC Major Business
2.7.3 Perrigo Company PLC Crohn鈥檚 Disease Therapeutics Product and Solutions
2.7.4 Perrigo Company PLC Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Perrigo Company PLC Recent Developments and Future Plans
2.8 Ferring B.V.
2.8.1 Ferring B.V. Details
2.8.2 Ferring B.V. Major Business
2.8.3 Ferring B.V. Crohn鈥檚 Disease Therapeutics Product and Solutions
2.8.4 Ferring B.V. Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Ferring B.V. Recent Developments and Future Plans
2.9 Salix Pharmaceuticals
2.9.1 Salix Pharmaceuticals Details
2.9.2 Salix Pharmaceuticals Major Business
2.9.3 Salix Pharmaceuticals Crohn鈥檚 Disease Therapeutics Product and Solutions
2.9.4 Salix Pharmaceuticals Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Salix Pharmaceuticals Recent Developments and Future Plans
2.10 Gilead Sciences Inc.
2.10.1 Gilead Sciences Inc. Details
2.10.2 Gilead Sciences Inc. Major Business
2.10.3 Gilead Sciences Inc. Crohn鈥檚 Disease Therapeutics Product and Solutions
2.10.4 Gilead Sciences Inc. Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Gilead Sciences Inc. Recent Developments and Future Plans
2.11 Genentech Inc.
2.11.1 Genentech Inc. Details
2.11.2 Genentech Inc. Major Business
2.11.3 Genentech Inc. Crohn鈥檚 Disease Therapeutics Product and Solutions
2.11.4 Genentech Inc. Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Genentech Inc. Recent Developments and Future Plans
2.12 UCB India Private Limited.
2.12.1 UCB India Private Limited. Details
2.12.2 UCB India Private Limited. Major Business
2.12.3 UCB India Private Limited. Crohn鈥檚 Disease Therapeutics Product and Solutions
2.12.4 UCB India Private Limited. Crohn鈥檚 Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 UCB India Private Limited. Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Crohn鈥檚 Disease Therapeutics Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Crohn鈥檚 Disease Therapeutics by Company Revenue
3.2.2 Top 3 Crohn鈥檚 Disease Therapeutics Players 麻豆原创 Share in 2023
3.2.3 Top 6 Crohn鈥檚 Disease Therapeutics Players 麻豆原创 Share in 2023
3.3 Crohn鈥檚 Disease Therapeutics 麻豆原创: Overall Company Footprint Analysis
3.3.1 Crohn鈥檚 Disease Therapeutics 麻豆原创: Region Footprint
3.3.2 Crohn鈥檚 Disease Therapeutics 麻豆原创: Company Product Type Footprint
3.3.3 Crohn鈥檚 Disease Therapeutics 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Crohn鈥檚 Disease Therapeutics Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Crohn鈥檚 Disease Therapeutics 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Crohn鈥檚 Disease Therapeutics Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Crohn鈥檚 Disease Therapeutics 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Crohn鈥檚 Disease Therapeutics Consumption Value by Type (2019-2030)
6.2 North America Crohn鈥檚 Disease Therapeutics Consumption Value by Application (2019-2030)
6.3 North America Crohn鈥檚 Disease Therapeutics 麻豆原创 Size by Country
6.3.1 North America Crohn鈥檚 Disease Therapeutics Consumption Value by Country (2019-2030)
6.3.2 United States Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Crohn鈥檚 Disease Therapeutics Consumption Value by Type (2019-2030)
7.2 Europe Crohn鈥檚 Disease Therapeutics Consumption Value by Application (2019-2030)
7.3 Europe Crohn鈥檚 Disease Therapeutics 麻豆原创 Size by Country
7.3.1 Europe Crohn鈥檚 Disease Therapeutics Consumption Value by Country (2019-2030)
7.3.2 Germany Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Crohn鈥檚 Disease Therapeutics Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Crohn鈥檚 Disease Therapeutics Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Crohn鈥檚 Disease Therapeutics 麻豆原创 Size by Region
8.3.1 Asia-Pacific Crohn鈥檚 Disease Therapeutics Consumption Value by Region (2019-2030)
8.3.2 China Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Crohn鈥檚 Disease Therapeutics Consumption Value by Type (2019-2030)
9.2 South America Crohn鈥檚 Disease Therapeutics Consumption Value by Application (2019-2030)
9.3 South America Crohn鈥檚 Disease Therapeutics 麻豆原创 Size by Country
9.3.1 South America Crohn鈥檚 Disease Therapeutics Consumption Value by Country (2019-2030)
9.3.2 Brazil Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Crohn鈥檚 Disease Therapeutics Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Crohn鈥檚 Disease Therapeutics Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Crohn鈥檚 Disease Therapeutics 麻豆原创 Size by Country
10.3.1 Middle East & Africa Crohn鈥檚 Disease Therapeutics Consumption Value by Country (2019-2030)
10.3.2 Turkey Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Crohn鈥檚 Disease Therapeutics 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Crohn鈥檚 Disease Therapeutics 麻豆原创 Drivers
11.2 Crohn鈥檚 Disease Therapeutics 麻豆原创 Restraints
11.3 Crohn鈥檚 Disease Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Crohn鈥檚 Disease Therapeutics Industry Chain
12.2 Crohn鈥檚 Disease Therapeutics Upstream Analysis
12.3 Crohn鈥檚 Disease Therapeutics Midstream Analysis
12.4 Crohn鈥檚 Disease Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Johnson and Johnson Services Inc.
Pfizer Inc.
Allergan
AbbVie Inc.
Takeda Pharmaceutical Company Limited
Celgene Corporation
Perrigo Company PLC
Ferring B.V.
Salix Pharmaceuticals
Gilead Sciences Inc.
Genentech Inc.
UCB India Private Limited.
听
听
*If Applicable.
